Tom 18, Nr 1 (2022)
Artykuł przeglądowy
Opublikowany online: 2022-04-24
Wyświetlenia strony 1957
Wyświetlenia/pobrania artykułu 318
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Zastosowanie blokad, kannabinoidów i metod pozafarmakologicznych w leczeniu migreny

Marta Waliszewska-Prosół1, Marcin Kopka2, Magdalena Nowaczewska34, Łukasz Kmieciak5, Marcin Straburzyński6
Pol. Przegl. Neurol 2022;18(1):1-20.

Streszczenie

Działania niepożądane, interakcje lekowe, a także farmakooporność mogą w znacznym stopniu utrudniać farmakologiczne leczenie migreny. W związku z tym coraz częściej stosuje się niekonwencjonalne i niefarmakologiczne metody leczenia. W szczególności nieinwazyjna neuromodulacja, blokady nerwów obwodowych, nutraceutyki i metody behawioralne są dobrze tolerowane i wskazane dla określonych grup pacjentów, takich jak młodzież, kobiety w ciąży i pacjenci, którzy z różnych powodów muszą lub chcą ograniczyć farmakoterapię. Metody te są coraz częściej postrzegane jako ważna opcja terapeutyczna w leczeniu migreny, konieczne są jednak dalsze badania nad ich skutecznością, także w odniesieniu do efektów długoter minowych, zwłaszcza że skuteczności części metod niekonwencjona lnych (np. kannabinoidów) dotychczas nie zweryfikowano w dobrej jakości badaniach naukowych.

Celem pracy jest przedstawienie i omówienie głównych metod wspomagających leczenie farmakologiczne migreny na podstawie aktualnego piśmiennictwa.

Artykuł dostępny w formacie PDF

Dodaj do koszyka: 49,00 PLN

Posiadasz dostęp do tego artykułu?

Referencje

  1. Steiner TJ, Stovner LJ, Vos T, et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018; 19(1): 17.
  2. Lipton RB, Manack A, Ricci JA, et al. Prevalence and burden of chronic migraine in adolescents: results of the chronic daily headache in adolescents study (C-dAS). Headache. 2011; 51(5): 693–706.
  3. Dodick D. Migraine. The Lancet. 2018; 391(10127): 1315–1330.
  4. Su D, Li L. Trends in the use of complementary and alternative medicine in the United States: 2002-2007. J Health Care Poor Underserved. 2011; 22(1): 296–301.
  5. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Rep. 2008; 10(12): 1–23.
  6. Raggi A, Grignani E, Leonardi M, et al. Behavioral approaches for primary headaches: recent advances. Headache. 2018; 58(6): 913–925.
  7. Lake AE, Saper JR, Hamel RL. Comprehensive inpatient treatment of refractory chronic daily headache. Headache. 2009; 49(4): 555–562.
  8. Grazzi L. Multidisciplinary approach to patients with chronic migraine and medication overuse: experience at the Besta Headache Center. Neurol Sci. 2013; 34 Suppl 1: S19–S21.
  9. Westergaard ML, Hansen EH, Glümer C, et al. Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. Cephalalgia. 2014; 34(6): 409–425.
  10. Gupta R, Fisher K, Pyati S. Chronic headache: a review of interventional treatment strategies in headache management. Curr Pain Headache Rep. 2019; 23(9): 68.
  11. Shauly O, Gould DJ, Sahai-Srivastava S, et al. Greater occipital nerve block for the treatment of chronic migraine headaches: a systematic review and meta-analysis. Plast Reconstr Surg. 2019; 144(4): 943–952.
  12. Solomon S, Guglielmo KM. Treatment of headache by transcutaneous electrical stimulation. Headache. 1985; 25(1): 12–15.
  13. Bronfort G, Nilsson N, Haas M, et al. Non-invasive physical treatments for chronic/recurrent headache. Cochrane Database Syst Rev. 2004(3): CD001878.
  14. Gerardy P, Fabry D, Fumal A, et al. pilot study on supra-orbital surface Eletrotherapy in migraine. Cephalalgia. 2009; 29: 134.
  15. Chou DE, Gross GJ, Casadei CH, et al. External trigeminal nerve stimulation for the acute treatment of migraine: open-label trial on safety and efficacy. Neuromodulation. 2017; 20(7): 678–683.
  16. Chou DE, Shnayderman Yugrakh M, Winegarner D, et al. Acute migraine therapy with external trigeminal neurostimulation (ACME): a randomized controlled trial. Cephalalgia. 2019; 39(1): 3–14.
  17. Schoenen J, Vandersmissen B, Jeangette S, et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology. 2013; 80(8): 697–704.
  18. Schoenen JE. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology. 2016; 86(2): 201–202.
  19. Russo A, Conte F, Marcuccio L, et al. P019. Transcutaneous supraorbital neurostimulation in “de novo” patients with migraine without aura: the first Italian experience. J Head Pain. 2015; 16(S1).
  20. Magis D, Sava S, d'Elia TS, et al. Safety and patients' satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly® device in headache treatment: a survey of 2,313 headache sufferers in the general population. J Headache Pain. 2013; 14: 95.
  21. Piquet M, Balestra C, Sava SL, et al. Supraorbital transcutaneous neurostimulation has sedative effects in healthy subjects. BMC Neurol. 2011; 11: 135.
  22. Barker AT, Jalinous R, Freeston IL. Non-invasive magnetic stimulation of human motor cortex. Lancet. 1985; 1(8437): 1106–1107.
  23. Chen R, Cros D, Curra A, et al. The clinical diagnostic utility of transcranial magnetic stimulation: report of an IFCN committee. Clin Neurophysiol. 2008; 119(3): 504–532.
  24. Leao AAP. Spreading depression of activity in cerebral cortex. J Neurophysiol. 1944; 7: 359–390.
  25. Barkley GL, Tepley N, Nagel-Leiby S, et al. Magnetoencephalographic studies of migraine. Headache. 1990; 30(7): 428–434.
  26. Misra UK, Kalita J, Bhoi SK. High-rate repetitive transcranial magnetic stimulation in migraine prophylaxis: a randomized, placebo-controlled study. J Neurol. 2013; 260(11): 2793–2801.
  27. Lipton RB, Dodick DW, Silberstein SD, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 2010; 9(4): 373–380.
  28. Ayata C, Jin H, Kudo C, et al. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol. 2006; 59(4): 652–661.
  29. Bhola R, Kinsella E, Giffin N, et al. Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program. J Headache Pain. 2015; 16: 535.
  30. Starling AJ, Tepper SJ, Marmura MJ, et al. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia. 2018; 38(6): 1038–1048.
  31. Brighina F, Piazza A, Vitello G, et al. rTMS of the prefrontal cortex in the treatment of chronic migraine: a pilot study. J Neurol Sci. 2004; 227(1): 67–71.
  32. Teepker M, Hötzel J, Timmesfeld N, et al. Low-frequency rTMS of the vertex in the prophylactic treatment of migraine. Cephalalgia. 2010; 30(2): 137–144.
  33. Speciali JG, Peres M, Bigal ME. Migraine treatment and placebo effect. Expert Rev Neurother. 2010; 10(3): 413–419.
  34. Dodick DW, Schembri CT, Helmuth M, et al. Transcranial magnetic stimulation for migraine: a safety review. Headache. 2010; 50(7): 1153–1163.
  35. Buse DC, Manack A, Serrano D, et al. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010; 81(4): 428–432.
  36. Schrader LM, Stern JM, Koski L, et al. Seizure incidence during single- and paired-pulse transcranial magnetic stimulation (TMS) in individuals with epilepsy. Clin Neurophysiol. 2004; 115(12): 2728–2737.
  37. Penry JK, Dean JC. Prevention of intractable partial seizures by intermittent vagal stimulation in humans: preliminary results. Epilepsia. 1990; 31(Suppl 2): S40–S43.
  38. Schachter SC, Saper CB. Vagus nerve stimulation. Epilepsia. 1998; 39(7): 677–686.
  39. Magis D, Vigano A, Sava S, et al. Neurostimulation therapy in intractable headaches. Handb Clin Neurol. 2010; 97(2): 443–450.
  40. Sadler RM, Purdy RA, Rahey S. Vagal nerve stimulation aborts migraine in patient with intractable epilepsy. Cephalalgia. 2002; 22(6): 482–484.
  41. Lenaerts ME, Oommen KJ, Couch JR, et al. Can vagus nerve stimulation help migraine? Cephalalgia. 2008; 28(4): 392–395.
  42. Hord ED, Evans MS, Mueed S, et al. The effect of vagus nerve stimulation on migraines. J Pain. 2003; 4(9): 530–534.
  43. Goadsby PJ, Grosberg BM, Mauskop A, et al. Effect of noninvasive vagus nerve stimulation on acute migraine: an open-label pilot study. Cephalalgia. 2014; 34(12): 986–993.
  44. Tassorelli C, Grazzi L, de Tommaso M, et al. PRESTO Study Group. Noninvasive vagus nerve stimulation as acute therapy for migraine: the randomized PRESTO study. Neurology. 2018; 91(4): e364–e373.
  45. Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001; 358(9294): 1668–1675.
  46. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015; 55(1): 3–20.
  47. Grazzi L, Egeo G, Calhoun AH, et al. Non-invasive vagus nerve stimulation (nVNS) as mini-prophylaxis for menstrual/menstrually related migraine: an open-label study. J Headache Pain. 2016; 17(1): 91.
  48. Kinfe TM, Pintea B, Muhammad S, et al. Cervical non-invasive vagus nerve stimulation (nVNS) for preventive and acute treatment of episodic and chronic migraine and migraine-associated sleep disturbance: A prospective obser-vational cohort study. J Headache Pain. 2015; 16: 101.
  49. Silberstein SD, Calhoun AH, Lipton RB, et al. EVENT Study Group. Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study. Neurology. 2016; 87(5): 529–538.
  50. Diener HC, Goadsby PJ, Ashina M, et al. Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial. Cephalalgia. 2019; 39(12): 1475–1487.
  51. Murphy JV. Left vagal nerve stimulation in children with medically refractory epilepsy. The Pediatric VNS Study Group. J Pediatr. 1999; 134(5): 563–566.
  52. Aaronson ST, Carpenter LL, Conway CR, et al. Vagus nerve stimulation therapy randomized to different amounts of electrical charge for treatment-resistant depression: acute and chronic effects. Brain Stimul. 2013; 6(4): 631–640.
  53. Chen SP, Ay I, Lopes de Morais A, et al. Vagus nerve stimulation inhibits cortical spreading depression. Pain. 2016; 157(4): 797–805.
  54. Oshinsky ML, Murphy AL, Hekierski H, et al. Noninvasive vagus nerve stimulation as treatment for trigeminal allodynia. Pain. 2014; 155(5): 1037–1042.
  55. electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Adolescent Migraine. https://investor.electrocore.com/news-releases/news-release-details/electrocore-announces-510k-clearance-gammacoretm-non-invasive (February 16, 2021).
  56. Grazzi L, Egeo G, Liebler E, et al. Non-invasive vagus nerve stimulation (nVNS) as symptomatic treatment of migraine in young patients: a preliminary safety study. Neurol Sci. 2017; 38(Suppl 1): 197–199.
  57. Yarnitsky D, Volokh L, Ironi A, et al. Nonpainful remote electrical stimulation alleviates episodic migraine pain. Neurology. 2017; 88(13): 1250–1255.
  58. Nierenburg H, Vieira JR, Lev N, et al. Remote electrical neuromodulation for the acute treatment of migraine in patients with chronic migraine: an open-label pilot study. Pain Ther. 2020; 9(2): 531–543.
  59. Hou AY, Chen A, Yuan H, et al. Peripheral neuromodulation for the treatment of migraine and headache: recent advances. Bioelectronics in Medicine. 2019; 2(4): 151–162.
  60. Bartsch T, Goadsby PJ. The trigeminocervical complex and migraine: current concepts and synthesis. Curr Pain Headache Rep. 2003; 7(5): 371–376.
  61. Allen SM, Mookadam F, Cha SS, et al. Greater occipital nerve block for acute treatment of migraine headache: a large retrospective cohort study. J Am Board Fam Med. 2018; 31(2): 211–218.
  62. Ashkenazi A, Blumenfeld A, Napchan U, et al. Interventional Procedures Special Interest Section of the American. Peripheral nerve blocks and trigger point injections in headache management — a systematic review and suggestions for future research. Headache. 2010; 50(6): 943–952.
  63. Viganò A, Torrieri MC, Toscano M, et al. Neurophysiological correlates of clinical improvement after greater occipital nerve (GON) block in chronic migraine: relevance for chronic migraine pathophysiology. J Headache Pain. 2018; 19(1): 73.
  64. Miller S, Lagrata S, Matharu M. Multiple cranial nerve blocks for the transitional treatment of chronic headaches. Cephalalgia. 2019; 39(12): 1488–1499.
  65. Blumenfeld A, Ashkenazi A, Napchan U, et al. Expert consensus recommendations for the performance of peripheral nerve blocks for headaches--a narrative review. Headache. 2013; 53(3): 437–446.
  66. Shah A, Morris S, Alexander B, et al. Landmark technique vs ultrasound-guided approach for posterior tibial nerve block in cadaver models. Indian J Orthop. 2020; 54(1): 38–42.
  67. Malekian N, Bastani PB, Oveisgharan S, et al. Preventive effect of greater occipital nerve block on patients with episodic migraine: A randomized double-blind placebo-controlled clinical trial. Cephalalgia. 2021 [Epub ahead of print]: 3331024211058182.
  68. Baron EP, Lucas P, Eades J, et al. Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. J Headache Pain. 2018; 19(1): 37.
  69. Van der Schueren BJ, Van Laere K, Gérard N, et al. Interictal type 1 cannabinoid receptor binding is increased in female migraine patients. Headache. 2012; 52(3): 433–440.
  70. Cupini LM, Costa C, Sarchielli P, et al. Degradation of endocannabinoids in chronic migraine and medication overuse headache. Neurobiol Dis. 2008; 30(2): 186–189.
  71. Greco R, Demartini C, Zanaboni AM, et al. Peripheral changes of endocannabinoid system components in episodic and chronic migraine patients: A pilot study. Cephalalgia. 2021; 41(2): 185–196.
  72. Rossi C, Pini LA, Cupini ML, et al. Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels. Eur J Clin Pharmacol. 2008; 64(1): 1–8.
  73. Sarchielli P, Pini LA, Coppola F, et al. Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacology. 2007; 32(6): 1384–1390.
  74. Juhasz G, Csepany E, Magyar M, et al. Variants in the CNR1 gene predispose to headache with nausea in the presence of life stress. Genes Brain Behav. 2017; 16(3): 384–393.
  75. Kazemi H, Rahgozar M, Speckmann EJ, et al. Effect of cannabinoid receptor activation on spreading depression. Iran J Basic Med Sci. 2012; 15(4): 926–936.
  76. Greco R, Mangione AS, Sandrini G, et al. Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model. J Headache Pain. 2014; 15: 14.
  77. Yamamoto T, Mulpuri Y, Izraylev M, et al. Selective targeting of peripheral cannabinoid receptors prevents behavioral symptoms and sensitization of trigeminal neurons in mouse models of migraine and medication overuse headache. Pain. 2021; 162(8): 2246–2262.
  78. Greco R, Demartini C, Zanaboni AM, et al. Endocannabinoid system and migraine pain: an update. Front Neurosci. 2018; 12: 172.
  79. Baron EP. Medicinal properties of cannabinoids, terpenes, and favonoids in cannabis, and benefits in migraine, headache, and pain: an update on current evidence and cannabis science. Headache. 2018; 58(7): 1139–1186.
  80. Aviram J, Vysotski Y, Berman P, et al. Migraine frequency decrease following prolonged medical cannabis treatment: a cross-sectional study. Brain Sci. 2020; 10(6).
  81. Rhyne DN, Anderson SL, Gedde M, et al. Effects of medical marijuana on migraine headache frequency in an adult population. Pharmacotherapy. 2016; 36(5): 505–510.
  82. Cuttler C, Spradlin A, Cleveland MJ, et al. Short- and long-term effects of cannabis on headache and migraine. J Pain. 2020; 21(5-6): 722–730.
  83. Stith SS, Diviant JP, Brockelman F, et al. Alleviative effects of Cannabis flower on migraine and headache. J Integr Med. 2020; 18(5): 416–424.
  84. Stępień A, Kozubski W, Rożniecki JJ, et al. Migraine treatment recommendations developed by an Expert Group of the Polish Headache Society, the Headache Section of the Polish Neurological Society, and the Polish Pain Society. Neurol Neurochir Pol. 2021; 55(1): 33–51.
  85. Kuruvilla D, Wells RE. Evidence-based integrative treatments for headache. Headache. 2019; 59(6): 971–972.
  86. Dolati S, Rikhtegar R, Mehdizadeh A, et al. The role of magnesium in pathophysiology and migraine treatment. Biol Trace Elem Res. 2020; 196(2): 375–383.
  87. D'Onofrio F, Raimo S, Spitaleri D, et al. Usefulness of nutraceuticals in migraine prophylaxis. Neurol Sci. 2017; 38(Suppl 1): 117–120.
  88. Peikert A, Wilimzig C, Köhne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia. 1996; 16(4): 257–263.
  89. Khani S, Hejazi SA, Yaghoubi M, et al. Comparative study of magnesium, sodium valproate, and concurrent magnesium-sodium valproate therapy in the prevention of migraine headaches: a randomized controlled double-blind trial. J Headache Pain. 2021; 22(1): 21.
  90. Mauskop A, Altura BT, Cracco RQ, et al. Intravenous magnesium sulphate relieves migraine attacks in patients with low serum ionized magnesium levels: a pilot study. Clin Sci (Lond). 1995; 89(6): 633–636.
  91. Meng SH, Zhou HB, Li X, et al. Dietary intake of calcium and magnesium in relation to severe headache or migraine. Front Nutr. 2021; 8: 653765.
  92. Slavin M, Li H, Khatri M, et al. Dietary magnesium and migraine in adults: a cross-sectional analysis of the National Health and Nutrition Examination Survey 2001-2004. Headache. 2021; 61(2): 276–286.
  93. Parohan M, Sarraf P, Javanbakht MH, et al. Effect of coenzyme Q10 supplementation on clinical features of migraine: a systematic review and dose-response meta-analysis of randomized controlled trials. Nutr Neurosci. 2020; 23(11): 868–875.
  94. Sazali S, Badrin S, Norhayati MN, et al. Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine — a meta-analysis. BMJ Open. 2021; 11(1): e039358.
  95. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology. 1998; 50(2): 466–470.
  96. Das R, Qubty W. Retrospective observational study on riboflavin prophylaxis in child and adolescent migraine. Pediatr Neurol. 2021; 114: 5–8.
  97. Talebian A, Soltani B, Banafshe HR, et al. Prophylactic effect of riboflavin on pediatric migraine: a randomized, double-blind, placebo-controlled trial. Electron Physician. 2018; 10(2): 6279–6285.
  98. Thompson DF, Saluja HS. Prophylaxis of migraine headaches with riboflavin: a systematic review. J Clin Pharm Ther. 2017; 42(4): 394–403.
  99. Nowaczewska M, Wiciński M, Osiński S, et al. The role of vitamin D in primary headache-from potential mechanism to treatment. Nutrients. 2020; 12(1).
  100. Ghorbani Z, Rafiee P, Fotouhi A, et al. The effects of vitamin D supplementation on interictal serum levels of calcitonin gene-related peptide (CGRP) in episodic migraine patients: post hoc analysis of a randomized double-blind placebo-controlled trial. J Headache Pain. 2020; 21(1): 22.
  101. Zhang YF, Xu ZQ, Zhou HJ, et al. The efficacy of vitamin D supplementation for migraine: a meta-analysis of randomized controlled studies. Clin Neuropharmacol. 2021; 44(1): 5–8.
  102. Diener HC, Rahlfs VW, Danesch U. The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. Eur Neurol. 2004; 51(2): 89–97.
  103. Lipton RB, Göbel H, Einhäupl KM, et al. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology. 2004; 63(12): 2240–2244.
  104. Wider B, Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev. 2015 [Epub ahead of print]; 4: CD002286.
  105. Ahmadi H, Mazloumi-Kiapey SS, Sadeghi O, et al. Zinc supplementation affects favorably the frequency of migraine attacks: a double-blind randomized placebo-controlled clinical trial. Nutr J. 2020; 19(1): 101.
  106. Naghibi MM, Day R, Stone S, et al. Probiotics for the prophylaxis of migraine: a systematic review of randomized placebo controlled trials. J Clin Med. 2019; 8(9).
  107. Gaul C, Diener HC, Danesch U, et al. Migravent® Study Group. Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. J Headache Pain. 2015; 16: 516.
  108. Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache. 2004; 44(9): 885–890.
  109. Parohan M, Sarraf P, Javanbakht MH, et al. The synergistic effects of nano-curcumin and coenzyme Q10 supplementation in migraine prophylaxis: a randomized, placebo-controlled, double-blind trial. Nutr Neurosci. 2021; 24(4): 317–326.
  110. Hajihashemi P, Askari G, Khorvash F, et al. The effects of concurrent coenzyme Q10, L-carnitine supplementation in migraine prophylaxis: a randomized, placebo-controlled, double-blind trial. Cephalalgia. 2019; 39(5): 648–654.
  111. Vikelis M, Dermitzakis EV, Vlachos GS, et al. Open label prospective experience of supplementation with a fixed combination of magnesium, vitamin B2, feverfew, andrographis paniculata and coenzyme Q10 for episodic migraine prophylaxis. J Clin Med. 2020; 10(1).
  112. Guilbot A, Bangratz M, Ait Abdellah S, et al. A combination of coenzyme Q10, feverfew and magnesium for migraine prophylaxis: a prospective observational study. BMC Complement Altern Med. 2017; 17(1): 433.
  113. Okoli GN, Rabbani R, Kashani HH, et al. Vitamins and minerals for migraine prophylaxis: a systematic review and meta-analysis. Can J Neurol Sci. 2019; 46(2): 224–233.
  114. Arzani M, Jahromi S, Ghorbani Z, et al. On behalf of the School of Advanced Studies of the European Headache Federation (EHF-SAS). Gut-brain Axis and migraine headache: a comprehensive review. J Headache Pain. 2020; 21(1).
  115. Razeghi Jahromi S, Ghorbani Z, Martelletti P, et al. School of Advanced Studies of the European Headache Federation (EHF-SAS). Association of diet and headache. J Headache Pain. 2019; 20(1): 106.
  116. Karsan N, Bose P, Goadsby PJ. The migraine premonitory phase. Continuum (Minneap Minn). 2018; 24(4, Headache): 996–1008.
  117. Nowaczewska M, Wiciński M, Kaźmierczak W, et al. To eat or not to eat: a review of the relationship between chocolate and migraines. Nutrients. 2020; 12(3).
  118. Nowaczewska M, Wiciński M, Kaźmierczak W. The ambiguous role of caffeine in migraine headache: from trigger to treatment. Nutrients. 2020; 12(8).
  119. Aydinlar EI, Dikmen PY, Tiftikci A, et al. IgG-based elimination diet in migraine plus irritable bowel syndrome. Headache. 2013; 53(3): 514–525.
  120. Mitchell N, Hewitt CE, Jayakody S, et al. Randomised controlled trial of food elimination diet based on IgG antibodies for the prevention of migraine like headaches. Nutr J. 2011; 10: 85.
  121. Alpay K, Ertas M, Orhan EK, et al. Diet restriction in migraine, based on IgG against foods: a clinical double-blind, randomised, cross-over trial. Cephalalgia. 2010; 30(7): 829–837.
  122. Ameghino L, Farez MF, Wilken M, et al. Headache in patients with celiac disease and its response to the guten-free diet. J Oral Facial Pain Headache. 2019; 33(3): 294–300.
  123. Beuthin J, Veronesi M, Grosberg B, et al. Gluten-free diet and migraine. Headache. 2020; 60(10): 2526–2529.
  124. Razeghi Jahromi S, Togha M, Ghorbani Z, et al. The association between dietary tryptophan intake and migraine. Neurol Sci. 2019; 40(11): 2349–2355.
  125. Grech O, Mollan SP, Wakerley BR, et al. The role of metabolism in migraine pathophysiology and susceptibility. Life (Basel). 2021; 11(5).
  126. Kossoff EH, Huffman J, Turner Z, et al. Use of the modified Atkins diet for adolescents with chronic daily headache. Cephalalgia. 2010; 30(8): 1014–1016.
  127. Bongiovanni D, Benedetto C, Corvisieri S, et al. Effectiveness of ketogenic diet in treatment of patients with refractory chronic migraine. Neurol Sci. 2021; 42(9): 3865–3870.
  128. Di Lorenzo C, Coppola G, Sirianni G, et al. Migraine improvement during short lasting ketogenesis: a proof-of-concept study. Eur J Neurol. 2015; 22(1): 170–177.
  129. Di Lorenzo C, Pinto A, Ienca R, et al. A randomized double-blind, cross-over trial of very low-calorie diet in overweight migraine patients: a possible role for ketones? Nutrients. 2019; 11(8).
  130. Evcili G, Utku U, Öğün MN, et al. Early and long period follow-up results of low glycemic index diet for migraine prophylaxis. Agri. 2018; 30(1): 8–11.
  131. Gelaye B, Sacco S, Brown WJ, et al. Body composition status and the risk of migraine: a meta-analysis. Neurology. 2017; 88(19): 1795–1804.
  132. Bunner AE, Agarwal U, Gonzales JF, et al. Nutrition intervention for migraine: a randomized crossover trial. J Headache Pain. 2014; 15: 69.
  133. Ramsden CE, Zamora D, Makriyannis A, et al. Diet-induced changes in n-3- and n-6-derived endocannabinoids and reductions in headache pain and psychological distress. J Pain. 2015; 16(8): 707–716.
  134. Lee HJ, Lee JH, Cho EY, et al. Efficacy of psychological treatment for headache disorder: a systematic review and meta-analysis. J Headache Pain. 2019; 20(1): 17.
  135. Perlini C, Donisi V, Del Piccolo L. From research to clinical practice: a systematic review of the implementation of psychological interventions for chronic headache in adults. BMC Health Serv Res. 2020; 20(1): 459.
  136. Harris P, Loveman E, Clegg A, et al. Systematic review of cognitive behavioural therapy for the management of headaches and migraines in adults. Br J Pain. 2015; 9(4): 213–224.
  137. Rausa M, Palomba D, Cevoli S, et al. Biofeedback in the prophylactic treatment of medication overuse headache: a pilot randomized controlled trial. J Headache Pain. 2016; 17(1): 87.
  138. Nestoriuc Y, Martin A, Rief W, et al. Biofeedback treatment for headache disorders: a comprehensive efficacy review. Appl Psychophysiol Biofeedback. 2008; 33(3): 125–140.
  139. Stokes DA, Lappin MS. Neurofeedback and biofeedback with 37 migraineurs: a clinical outcome study. Behav Brain Funct. 2010; 6: 9.
  140. Blume HK, Brockman LN, Breuner CC. Biofeedback therapy for pediatric headache: factors associated with response. Headache. 2012; 52(9): 1377–1386.
  141. Pérez-Muñoz A, Buse DC, Andrasik F. Behavioral interventions for migraine. Neurol Clin. 2019; 37(4): 789–813.
  142. Nicholson RA, Buse DC, Andrasik F, et al. Nonpharmacologic treatments for migraine and tension-type headache: how to choose and when to use. Curr Treat Options Neurol. 2011; 13(1): 28–40.
  143. Vekhter D, Robbins MS, Minen M, et al. Efficacy and feasibility of behavioral treatments for migraine, headache, and pain in the acute care setting. Curr Pain Headache Rep. 2020; 24(10): 66.
  144. Sun-Edelstein C, Mauskop A. Alternative headache treatments: nutraceuticals, behavioral and physical treatments. Headache. 2011; 51(3): 469–483.
  145. Perlini C, Donisi V, Del Piccolo L. From research to clinical practice: a systematic review of the implementation of psychological interventions for chronic headache in adults. BMC Health Serv Res. 2020; 20(1): 459.
  146. Onur O, Ertem DH, Uludüz D, et al. Cognitive behavioral therapy for chronic migraine. Eur Psychiatry. 2017; 41(Suppl): s500.
  147. Kroner JW, Peugh J, Kashikar-Zuck SM, et al. Trajectory of improvement in children and adolescents with chronic migraine: results from the cognitive-behavioral therapy and amitriptyline trial. J Pain. 2017; 18(6): 637–644.
  148. Andrasik F, Grazzi L, D'Amico D, et al. Mindfulness and headache: a "new" old treatment, with new findings. Cephalalgia. 2016; 36(12): 1192–1205.
  149. Cathcart S, Galatis N, Immink M, et al. Brief mindfulness-based therapy for chronic tension-type headache: a randomized controlled pilot study. Behav Cogn Psychother. 2014; 42(1): 1–15.
  150. Grazzi L, Sansone E, Raggi A, et al. Mindfulness and pharmacological prophylaxis after withdrawal from medication overuse in patients with Chronic Migraine: an effectiveness trial with a one-year follow-up. J Headache Pain. 2017; 18(1): 15.
  151. Vekhter D, Robbins MS, Minen M, et al. Efficacy and feasibility of behavioral treatments for migraine, headache, and pain in the acute care setting. Curr Pain Headache Rep. 2020; 24(10): 66.
  152. Hayes SC, Luoma JB, Bond FW, et al. Acceptance and commitment therapy: model, processes and outcomes. Behav Res Ther. 2006; 44(1): 1–25.
  153. Hughes LS, Clark J, Colclough JA, et al. Acceptance and commitment therapy (ACT) for chronic pain: a systematic review and meta-analyses. Clin J Pain. 2017; 33(6): 552–568.
  154. Kuba K, Weissflog G. [Acceptance and commitment therapy in the treatment of chronic disease] [Article in German] . Psychother Psychosom Med Psychol. 2017; 67(12): 525–536.
  155. Grazzi L, Toppo C, D'Amico D, et al. Non-pharmacological approaches to headaches: non-invasive neuromodulation, nutraceuticals, and behavioral approaches. Int J Environ Res Public Health. 2021; 18(4).